I suspect though that Iron and various other rational longs (a disjoint subset from the longs who think the Earth revolves around NWBO) get tired of them making NWBO look like a cult stock for drunk college kids.
One NWBO cult member post makes me want to sell all my NWBO shares at a loss faster than 1000 Exwannebe posts will ever be able to do. Go figure.
And the recent green light for the expansion of the pembrolizumab combo research has brought some focus back on the Merck dot connecting too! Grant-funded trials are peer-reviewed, and the reviewers generally approve funding/expansion based on preliminary data. Notably, the PII trials at Roswell Park have been approved to expand in scope.. and look who joked on X about the overly-rigorous peer-review process for grant funding—the principal investigator of one of the Roswell trials!
Reviewers asking for prelim data when the grant mechanism says “prelim data not required” pic.twitter.com/qrBBnIvedt
So, it looks like the grant peer reviewers have been watching the PII trials closely 🤔 …
Since the peer-reviewed Roswell trials include pembrolizumab, we are a bit curious about Merck’s interest and awareness of DC platforms and how emerging interim data might lead to new combo possibilities…
These three scientists have coauthored several publications on dendritic cell vaccines, and all three were recently recruited by Merck in 2023 and 2024: ☑️ Juraj Adamik ☑️ Paul Munson ☑️ Lisa H. Butterfield
The trial scope and title were expanded to include hormone receptor-positive (HR+) breast cancer, the most common subtype.
☑️ Increased Patient Eligibility: A broader population now qualifies.
☑️ Scientific Implications: Potential efficacy beyond TNBC and HER2+ cases, possibly due to shared immune mechanisms.
☑️ Regulatory & Market Impact: Broader applicability could enhance approval prospects and market potential.
☑️ Trial Design Adjustments: May involve new stratification to account for differences in tumor biology.
Dr. Kabraji recently mentioned and cited the pembrolizumab + DC vaccine trial in a passing comment on X in response to someone on another topic, but I found his comment insightful considering the date of his X reply post and the context of the recent trial updates…his post was just weeks before he became the principal investigator of that trial…
Ongoing clinical trial @RoswellPark led by @gandhi_shipra for pts with asymptomatic #bcsm brain mets has changed our practice. Can’t change therapy unless these patients are entered into trial but entry requires screening brain MRI https://t.co/3QlS0DgVgz
I find your presense her humorous. Saving everyone from themselves, yet.... most longs are very likely (100% confident that I am) financially secure beyond your means/wildest imagination. But thanks for your concern. Hey, St. Patty's day tomorrow, gotta run, hostin 20 of my closest friends, gotta prep 4 waygu corned beef's. Cheers fellas.